Nicol G M Oonk1, Kris L L Movig2, Job van der Palen3,4, Henk-Willem Nijmeijer5, Mirjam E van Kesteren6, Lucille D A Dorresteijn7. 1. Department of Neurology, Medisch Spectrum Twente, Enschede, The Netherlands. n.oonk@mst.nl. 2. Department of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, The Netherlands. 3. Department of Epidemiology, Medisch Spectrum Twente, Enschede, The Netherlands. 4. Department of Research Methodology, Measurement, and Data Analysis, University of Twente, Enschede, The Netherlands. 5. Department of Neurology, Ziekenhuis Groep Twente, Almelo, The Netherlands. 6. Department of Neurology, Isala, Zwolle, The Netherlands. 7. Department of Neurology, Medisch Spectrum Twente, Enschede, The Netherlands.
Abstract
BACKGROUND AND OBJECTIVES: Quality of life (QoL) in Parkinson's disease (PD) depends on multiple factors. Due to PD treatment and accompanying, age-related or independent comorbidities, pill burden is often high. The relation of QoL and pharmacotherapy for comorbidities in PD has not been widely studied. This study investigated if and to what extent non-dopaminergic drugs are related to QoL in PD. Second, the impact of demographics and non-motor symptoms were evaluated. A better understanding of the impact of different non-dopaminergic drugs and polypharmacy on QoL will have added value in selecting appropriate (medication) interventions. METHODS: In a cross-sectional analysis, medication prescription data of 209 PD patients were analyzed and grouped according to the Rx-Risk comorbidity index. QoL was measured using the PDQ-39 questionnaire. Non-motor symptoms were analyzed with the Non-Motor Symptoms questionnaire. Independent factors associated with a reduced QoL were identified with a multivariate linear regression analysis. RESULTS: Non-dopaminergic drugs, subdivided into Rx-Risk comorbidity categories, were not associated with reduced QoL, except for the use of anti-epileptic drugs. However, using more daily non-dopaminergic drugs was also negatively associated with QoL, as well as female sex, increased PD severity, and more non-motor symptoms. Contraindicated non-dopaminergic medication was barely prescribed (0.4%). CONCLUSION: Non-dopaminergic drugs are frequently prescribed, and higher numbers are associated with impaired QoL in PD. However, when divided in drug types, only anti-epileptic drugs were negatively associated with QoL. In these patients, physicians might improve QoL by further optimizing the condition it was prescribed for (e.g., pain or anxiety), or managing of side effects. TRIAL REGISTRATION: Netherlands Trial Register; NL4360.
BACKGROUND AND OBJECTIVES: Quality of life (QoL) in Parkinson's disease (PD) depends on multiple factors. Due to PD treatment and accompanying, age-related or independent comorbidities, pill burden is often high. The relation of QoL and pharmacotherapy for comorbidities in PD has not been widely studied. This study investigated if and to what extent non-dopaminergic drugs are related to QoL in PD. Second, the impact of demographics and non-motor symptoms were evaluated. A better understanding of the impact of different non-dopaminergic drugs and polypharmacy on QoL will have added value in selecting appropriate (medication) interventions. METHODS: In a cross-sectional analysis, medication prescription data of 209 PDpatients were analyzed and grouped according to the Rx-Risk comorbidity index. QoL was measured using the PDQ-39 questionnaire. Non-motor symptoms were analyzed with the Non-Motor Symptoms questionnaire. Independent factors associated with a reduced QoL were identified with a multivariate linear regression analysis. RESULTS: Non-dopaminergic drugs, subdivided into Rx-Risk comorbidity categories, were not associated with reduced QoL, except for the use of anti-epileptic drugs. However, using more daily non-dopaminergic drugs was also negatively associated with QoL, as well as female sex, increased PD severity, and more non-motor symptoms. Contraindicated non-dopaminergic medication was barely prescribed (0.4%). CONCLUSION: Non-dopaminergic drugs are frequently prescribed, and higher numbers are associated with impaired QoL in PD. However, when divided in drug types, only anti-epileptic drugs were negatively associated with QoL. In these patients, physicians might improve QoL by further optimizing the condition it was prescribed for (e.g., pain or anxiety), or managing of side effects. TRIAL REGISTRATION: Netherlands Trial Register; NL4360.
Authors: D Santos García; E Suárez Castro; I Expósito; T de Deus; C Tuñas; A Aneiros; M López Fernández; D Núñez Arias; M Bermúdez Torres Journal: J Neurol Sci Date: 2016-12-29 Impact factor: 3.181
Authors: Cynthia L Leibson; Demetrius M Maraganore; James H Bower; Jeanine E Ransom; Peter C O'brien; Walter A Rocca Journal: Mov Disord Date: 2006-04 Impact factor: 10.338
Authors: E R Dorsey; R Constantinescu; J P Thompson; K M Biglan; R G Holloway; K Kieburtz; F J Marshall; B M Ravina; G Schifitto; A Siderowf; C M Tanner Journal: Neurology Date: 2006-11-02 Impact factor: 9.910
Authors: N G M Oonk; K L L Movig; E M Munster; K Koehorst-Ter Huurne; J van der Palen; L D A Dorresteijn Journal: Contemp Clin Trials Commun Date: 2018-11-28